Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.

Martínez O, Bravo Cruz A, Santos S, Ramírez M, Miranda E, Shisler J, Otero M.

Vaccine. 2017 Oct 20;35(44):6007-6014. doi: 10.1016/j.vaccine.2017.05.091. Epub 2017 Jun 16.

2.

Defending against smallpox: a focus on vaccines.

Voigt EA, Kennedy RB, Poland GA.

Expert Rev Vaccines. 2016 Sep;15(9):1197-211. doi: 10.1080/14760584.2016.1175305. Epub 2016 Apr 28. Review.

3.

Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized Screening.

Stern D, Pauly D, Zydek M, Miller L, Piesker J, Laue M, Lisdat F, Dorner MB, Dorner BG, Nitsche A.

PLoS One. 2016 Mar 1;11(3):e0150110. doi: 10.1371/journal.pone.0150110. eCollection 2016.

4.

DNA immunization.

Wang S, Lu S.

Curr Protoc Microbiol. 2013 Nov 5;31:18.3.1-18.3.24. doi: 10.1002/9780471729259.mc1803s31.

5.

Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.

Paran N, Lustig S, Zvi A, Erez N, Israely T, Melamed S, Politi B, Ben-Nathan D, Schneider P, Lachmi B, Israeli O, Stein D, Levin R, Olshevsky U.

Virol J. 2013 Jul 10;10:229. doi: 10.1186/1743-422X-10-229.

6.

Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, Buchman GW, Volkin DB, Middaugh CR, Isaacs SN.

Vaccine. 2013 Jan 2;31(2):319-26. doi: 10.1016/j.vaccine.2012.11.007. Epub 2012 Nov 12.

7.

Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.

Golden JW, Josleyn M, Mucker EM, Hung CF, Loudon PT, Wu TC, Hooper JW.

PLoS One. 2012;7(7):e42353. doi: 10.1371/journal.pone.0042353. Epub 2012 Jul 31.

8.

Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.

Tan X, Chun S, Pablo J, Felgner P, Liang X, Davies DH.

Clin Vaccine Immunol. 2012 Mar;19(3):418-28. doi: 10.1128/CVI.05521-11. Epub 2012 Jan 18.

9.

Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R, Molina DM, Felgner PL, Liang X, Davies DH.

Vaccine. 2012 Jan 11;30(3):614-25. doi: 10.1016/j.vaccine.2011.11.021. Epub 2011 Nov 17.

10.

Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW.

Virol J. 2011 Sep 20;8:441. doi: 10.1186/1743-422X-8-441.

11.

An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.

Xu C, Meng X, Yan B, Crotty S, Deng J, Xiang Y.

Virology. 2011 Sep 15;418(1):67-73. doi: 10.1016/j.virol.2011.06.029. Epub 2011 Aug 2.

12.

Smallpox vaccines: targets of protective immunity.

Moss B.

Immunol Rev. 2011 Jan;239(1):8-26. doi: 10.1111/j.1600-065X.2010.00975.x. Review.

13.

Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus.

Meng X, Zhong Y, Embry A, Yan B, Lu S, Zhong G, Xiang Y.

Virology. 2011 Jan 20;409(2):271-9. doi: 10.1016/j.virol.2010.10.019. Epub 2010 Nov 5.

14.

Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.

Golden JW, Hooper JW.

Clin Vaccine Immunol. 2010 Nov;17(11):1656-65. doi: 10.1128/CVI.00235-10. Epub 2010 Sep 15.

15.

A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2010 Sep 14;28(40):6627-36. doi: 10.1016/j.vaccine.2010.07.030. Epub 2010 Jul 24.

16.
17.

Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

McCausland MM, Benhnia MR, Crickard L, Laudenslager J, Granger SW, Tahara T, Kubo R, Koriazova L, Kato S, Crotty S.

Antivir Ther. 2010;15(4):661-75. doi: 10.3851/IMP1573.

18.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

19.

Smallpox vaccines for biodefense.

Kennedy RB, Ovsyannikova I, Poland GA.

Vaccine. 2009 Nov 5;27 Suppl 4:D73-9. doi: 10.1016/j.vaccine.2009.07.103. Review.

20.

Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI.

Vaccine. 2009 Dec 11;28(2):494-511. doi: 10.1016/j.vaccine.2009.09.133. Epub 2009 Oct 13.

Supplemental Content

Support Center